Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06880770 · ClinicalTrials.gov registry record · Phase 3

Study of Plozasiran in Adults With Severe Hypertriglyceridemia at Risk of Acute Pancreatitis

A Phase 3 study of Severe Hypertriglyceridemia, sponsored by Arrowhead Pharmaceuticals.

Recruiting
Registry status
Phase 3
Development phase
288
Enrollment target
20
Study locations

NCT06880770: Recruiting Phase 3 study of Severe Hypertriglyceridemia, sponsored by Arrowhead Pharmaceuticals.

NCT06880770 is a Phase 3 study of Severe Hypertriglyceridemia that is actively recruiting participants, run by Arrowhead Pharmaceuticals. The registered enrollment target is 288 participants, below the 389-participant average among 8 other Severe Hypertriglyceridemia trials with a reported enrollment target (26% lower). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06880770, a Phase 3 study of Severe Hypertriglyceridemia, is actively recruiting participants, sponsored by Arrowhead Pharmaceuticals.

RECRUITING
Registry status
Phase 3
Development phase
288 participants
Enrollment target
20
Study locations

Study Summary

This study will evaluate the efficacy and safety of plozasiran in approximately 288 adult participants with severe hypertriglyceridemia (SHTG) and history of at least two prior acute pancreatitis (AP) events not attributed to other etiologies, with at least one occurring within the last 12 months prior to screening. Eligible participants will be randomly assigned in a double-blind manner to either receive plozasiran 25 mg by subcutaneous (SC) injection every three months (Q3M) or matching placebo. Enrolled participants will be counseled to remain on the specified low-fat diet and background medications throughout the study. Following completion of the double-blind treatment period, or if the participant has a positively adjudicated AP event (whichever occurs first), participants will transition to the 12-month Open-Label Extension (OLE) treatment period receiving plozasiran 25 mg by SC injection Q3M.

Conditions Studied

Severe Hypertriglyceridemia

Interventions

  • DRUG Placebo
  • DRUG Plozasiran

Study Locations (20)

Minas Gerais

  • Research Site - Belo Horizonte
  • Research Site - Belo Horizonte
  • Research Site - Belo Horizonte

California

  • Research Site - Los Angeles
  • Clinical Research Site 4 - Santa Clarita

North Carolina

  • Clinical Research Site 3 - Greensboro
  • Research Site - Wilmington

Texas

  • Clinical Research Site 1 - Mesquite
  • Clinical Research Site 2 - San Antonio

Other

  • Research Site - Graz
  • Research Site - Burgas

Rio Grande do Sul

  • Research Site - Porto Alegre
  • Research Site - Pôrto Alegre

Illinois

  • Clinical Research Site 6 - Springfield

Indiana

  • Research Site - Indianapolis

Trial Details

FieldValue
Enrollment Target 288 participants
Start Date 2025-04-24
Est. Completion 2029-06
Phase Phase 3
Arrowhead Pharmaceuticals

15 total trials

What NCT06880770 shows while recruiting

NCT06880770 is an interventional study that assigns participants to a tested intervention. The registered 288 participants enrollment target is mid-sized for trials with a published cap, below the 389-participant average among 8 other Severe Hypertriglyceridemia trials with a reported enrollment target (26% lower).

The record links to 1 condition, with Severe Hypertriglyceridemia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT06880770 names 20 study sites across 13 states, led by Minas Gerais, California, North Carolina.

Frequently Asked Questions

What is clinical trial NCT06880770 about?

NCT06880770 is a clinical study titled "Study of Plozasiran in Adults With Severe Hypertriglyceridemia at Risk of Acute Pancreatitis". This study will evaluate the efficacy and safety of plozasiran in approximately 288 adult participants with severe hypertriglyceridemia (SHTG) and history of at least two prior acute pancreatitis (AP) events not attributed to other etiologies, with at least one occurring within the last 12 months pr...

What is the current status of trial NCT06880770?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 288 participants. The study started on 2025-04-24. Estimated completion is 2029-06.

What conditions does trial NCT06880770 study?

This clinical trial studies the following conditions: Severe Hypertriglyceridemia.

What interventions are being tested in trial NCT06880770?

The interventions under investigation include: Placebo (DRUG), Plozasiran (DRUG).

Who is sponsoring clinical trial NCT06880770?

This trial is sponsored by Arrowhead Pharmaceuticals, which has 15 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06880770 being conducted?

This trial has 20 study locations across California, Illinois, Indiana, Kansas, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Severe Hypertriglyceridemia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06880770's enrollment target sits among peer trials

288 7th of 8 higher than 2 of 8 other Severe Hypertriglyceridemia trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Severe Hypertriglyceridemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02098265 · 288 participants · NA

    A Closed Loop Neural Activity Triggered Stroke Rehabilitation Device

  • NCT03741777 · 288 participants · NA

    Comparison of Residual Gastric Volume Between Children Who Drink Different Clear Oral Fluid Volume

  • NCT03937635 · 288 participants · Phase 3

    Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma

  • NCT04621877 · 288 participants · NA

    Lay-Delivered Behavioral Activation in Senior Centers

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT06880770

Source: ClinicalTrials.gov NCT06880770, the US trial registry maintained by the National Library of Medicine. NCT06880770 (mid enrollment · wide site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.